Heuser Richard R
St. Luke's Medical Center, University of Arizona, College of Medicine, 555 N 18th St, Suite 300, Phoenix, AZ 85006.
Prog Cardiovasc Dis. 2017 May-Jun;59(6):549-554. doi: 10.1016/j.pcad.2017.05.002. Epub 2017 May 11.
Even though cardiovascular disease (CVD) is still the leading cause of death in the United States, stroke is the second leading global cause of death behind CVD. In the 21st Century, less than 40% of overall stroke patients are discharged to home and almost 25% of Medicare beneficiaries do not survive 90 days. In spite of the fact that tissue plasminogen activator (TPA) has been approved for stroke care for 20 years, only .75% of annual strokes are actually treated with intravenous (IV) TPA. Similar to how interventional cardiologists evolved from IV to catheter mechanical treatment for acute myocardial infarctions (AMI) over 30 years ago, over the last few years, neurointerventionists now perform endovascular stroke therapy in many of these patients using stent retrievers. However, very few stroke patients are actually getting treatment, and neurointerventionists on an average perform only 8 stroke interventions per year. It has been recently shown that 9 out of 10 strokes can be prevented by controlling CVD risk factors. A principal job for cardiologists is to recognize and manage these CVD risk factors in addition to being involved with performing intervention. Atrial Fibrillation is certainly a common problem in all of our practices and puts people at five-fold higher risk of stroke. Cardiovascular cardiology teams already have 24/7 coverage for acute interventions for AMI in place at their facilities. A number of groups have replicated acute stroke care performed by cardiologists at centers worldwide with outstanding results. It makes sense that we try to build a collaboration among neuroradiologists, interventional cardiologists and perhaps vascular or neurosurgeons with expertise in acute endovascular procedures to develop programs for acute and active 24/7 stroke care similar to systems for primary angioplasty for AMI.
尽管心血管疾病(CVD)在美国仍是主要死因,但中风是全球仅次于CVD的第二大死因。在21世纪,总体中风患者中不到40%出院回家,近25%的医疗保险受益人活不过90天。尽管组织纤溶酶原激活剂(TPA)已被批准用于中风治疗20年,但实际上每年只有0.75%的中风患者接受静脉注射(IV)TPA治疗。类似于30多年前介入心脏病专家从静脉注射治疗急性心肌梗死(AMI)发展到导管机械治疗,在过去几年里,神经介入专家现在使用支架取栓器对许多此类患者进行血管内中风治疗。然而,实际上接受治疗的中风患者非常少,神经介入专家平均每年仅进行8次中风干预。最近的研究表明,十分之九的中风可以通过控制CVD风险因素来预防。心脏病专家的一项主要工作除了参与干预外,还包括识别和管理这些CVD风险因素。心房颤动在我们所有的临床实践中肯定是一个常见问题,会使人们中风的风险增加五倍。心血管心脏病团队已经在其设施中为AMI的急性干预提供全天候服务。许多团队在世界各地的中心复制了心脏病专家进行的急性中风护理,取得了出色的成果。我们尝试在神经放射科医生、介入心脏病专家以及可能在急性血管内手术方面具有专业知识的血管外科医生或神经外科医生之间建立合作,以开发类似于AMI初级血管成形术系统的急性和全天候积极中风护理项目,这是有意义的。